Recombinant Human ENPP-1 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6136-EN

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
6136-EN-010
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

P22413 (ENPP-1) & Q13822 (ENPP-2)

Conjugate

Unconjugated

Applications

Enzyme Activity

View all ENPP-1 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human ENPP-1 protein

His ENPP-2
Asp49-Trp144
Accession # Q13822		 ENPP-1
Val191-Leu591
  Accession # P22413 		 ENPP-2
Asn532-Ile863
Accession # Q13822
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

His

Predicted Molecular Mass

96 kDa

SDS-PAGE

100-135 kDa, reducing conditions

Activity

Measured by its ability to hydrolyze thymidine 5'-monophosphate p-nitrophenyl ester.
The specific activity is >35,000 pmol/min/μg, as measured under the described conditions.

Reviewed Applications

Read 1 review rated 5 using 6136-EN in the following applications:

Formulation, Preparation and Storage

6136-EN
Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: ENPP-1

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP-1) is a transmembrane glycoprotein that hydrolyzes nucleotides and nucleotide derivatives with the formation of nucleotide-5’-monophosphates. It is inserted into the plasma membrane by an N‑terminal transmembrane domain. Human ENPP-1 has a small N-terminal cytoplasmic domain and a large C-terminal region containing two somatomedin B-like domains, a catalytic domain and a nuclease-like domain in the extracellular space (1). Defects in the ENPP-1 gene cause arterial calcification and bone mineralization abnormalities (2). ENPP-1 polymorphism or overexpression is also associated with obesity, type II diabetes and insulin resistance, which makes modulation of ENPP-1 activity one of the targets to treat insulin resistance and related diseases (1). The recombinant hybrid enzyme recombinant human ENPP-1 consists of N-terminal somatomedin B-like domains of ENPP-2, the central catalytic phosphodiesterase domain of ENPP-1 and the C‑terminal nuclease-like domain of ENPP-2. It has been reported that this hybrid construct generates an enzyme that has higher levels of ENPP-1 activity than the wild type ENPP-1 and is specific for the ENPP-1 substrate (3).

References

  1. Goldfine, I.D. et al. (2010) Endocrine Reviews. 29:62.
  2. Hessle, L. et al. (2002) Proc. Natl. Acad. Sci. 99:9445.
  3. Anisoara, C. et al. (2004) Biochem. J. 381:71.

Long Name

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1

Alternate Names

ENPP1, Ly-41 Antigen, M6S1, NPP1, NPPS, PCA1, PDNP1

Entrez Gene IDs

5167 (Human); 18605 (Mouse)

Gene Symbol

ENPP1

UniProt

P22413 (ENPP-1) & Q13822 (ENPP-2)

Additional ENPP-1 Products

Product Documents for Recombinant Human ENPP-1 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human ENPP-1 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.